[Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003848
German
Original Title:
Durvalumab (kleinzelliges Lungenkarzinom) - 2. Addendum zum Auftrag A20-87
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a21-19.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/a21-19_durvalumab_addendum-zum-auftrag-a20-87_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Carcinoma, Small Cell
- Small Cell Lung Carcinoma
- Lung Neoplasms
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Keywords
- Durvalumab
- Etoposide
- Carboplatin
- Cisplatin
- Small Cell Lung Carcinoma
- Benefit Assessment
- NCT03043872
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.